maleic-acid and Hemolysis

maleic-acid has been researched along with Hemolysis* in 2 studies

Other Studies

2 other study(ies) available for maleic-acid and Hemolysis

Article	Year
Synthesis and evaluation of styrene-maleic acid copolymer conjugated amphotericin B. International journal of pharmaceutics, 2019, Dec-15, Volume: 572 Topics: Amphotericin B; Animals; Antifungal Agents; Drug Liberation; Erythrocytes; Hemolysis; Lethal Dose 50; Male; Maleates; Mice; Micelles; Saccharomyces cerevisiae; Solubility; Styrene	2019
pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice. ACS applied materials & interfaces, 2015, Dec-09, Volume: 7, Issue:48 In the present study, we have synthesized poly(styrene-co-maleic anhydride), a biocompatible copolymer that was further conjugated with paclitaxel (PTX) via ester linkage and self-assembled to form poly(styrene-co-maleic acid)-paclitaxel (PSMAC-PTX) nanoparticles (NPs). The in vitro release of PTX from PSMAC-PTX NPs showed a higher release at lower pH than at the physiological pH of 7.4, confirming its pH-dependent release. The cell viability of PSMAC-PTX nanoparticles was evaluated using MTT assay. IC50 values of 9.05-18.43 ng/mL of PTX equivalent were observed in various cancer cell lines after 72 h of incubation. Confocal microscopy, Western blotting, and Flow cytometry results further supported that the cellular uptake and apoptosis of cancer cells with PSMAC-PTX NPs. Pharmacokinetic studies revealed that the conjugation of PTX to the PSMAC co-polymer not only increased the plasma and tumor C(max) of PTX but also prolonged its plasma half-life and retention in tumor via enhanced permeability and retention (EPR) effect. Administration of PSMAC-PTX NPs showed significant tumor growth inhibition with improved apoptosis effects in vivo on Ehrlich Ascites Tumor (EAT)-bearing BALB/c syngeneic mice in comparison with Taxol, without showing any cytotoxicity. On the basis of preliminary results, no subacute toxicity was observed in major organs, tissues and hematological system up to a dosage of 60 mg/kg body weight in mice. Therefore, PSMAC-PTX NPs may be considered as an alternative nanodrug delivery system for the delivery of PTX in solid tumors. Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biocompatible Materials; Blood Cell Count; Body Weight; Carcinoma, Ehrlich Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Stability; Endocytosis; Erythrocyte Aggregation; Hemolysis; Hydrogen-Ion Concentration; In Situ Nick-End Labeling; Inhibitory Concentration 50; Kaplan-Meier Estimate; Maleates; Maximum Tolerated Dose; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polystyrenes; Tissue Distribution	2015

Article

Year

Synthesis and evaluation of styrene-maleic acid copolymer conjugated amphotericin B.

International journal of pharmaceutics, 2019, Dec-15, Volume: 572

Topics: Amphotericin B; Animals; Antifungal Agents; Drug Liberation; Erythrocytes; Hemolysis; Lethal Dose 50; Male; Maleates; Mice; Micelles; Saccharomyces cerevisiae; Solubility; Styrene

2019

pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.

ACS applied materials & interfaces, 2015, Dec-09, Volume: 7, Issue:48

In the present study, we have synthesized poly(styrene-co-maleic anhydride), a biocompatible copolymer that was further conjugated with paclitaxel (PTX) via ester linkage and self-assembled to form poly(styrene-co-maleic acid)-paclitaxel (PSMAC-PTX) nanoparticles (NPs). The in vitro release of PTX from PSMAC-PTX NPs showed a higher release at lower pH than at the physiological pH of 7.4, confirming its pH-dependent release. The cell viability of PSMAC-PTX nanoparticles was evaluated using MTT assay. IC50 values of 9.05-18.43 ng/mL of PTX equivalent were observed in various cancer cell lines after 72 h of incubation. Confocal microscopy, Western blotting, and Flow cytometry results further supported that the cellular uptake and apoptosis of cancer cells with PSMAC-PTX NPs. Pharmacokinetic studies revealed that the conjugation of PTX to the PSMAC co-polymer not only increased the plasma and tumor C(max) of PTX but also prolonged its plasma half-life and retention in tumor via enhanced permeability and retention (EPR) effect. Administration of PSMAC-PTX NPs showed significant tumor growth inhibition with improved apoptosis effects in vivo on Ehrlich Ascites Tumor (EAT)-bearing BALB/c syngeneic mice in comparison with Taxol, without showing any cytotoxicity. On the basis of preliminary results, no subacute toxicity was observed in major organs, tissues and hematological system up to a dosage of 60 mg/kg body weight in mice. Therefore, PSMAC-PTX NPs may be considered as an alternative nanodrug delivery system for the delivery of PTX in solid tumors.

Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biocompatible Materials; Blood Cell Count; Body Weight; Carcinoma, Ehrlich Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Stability; Endocytosis; Erythrocyte Aggregation; Hemolysis; Hydrogen-Ion Concentration; In Situ Nick-End Labeling; Inhibitory Concentration 50; Kaplan-Meier Estimate; Maleates; Maximum Tolerated Dose; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polystyrenes; Tissue Distribution

2015